EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America

Michelle Weisfelner Bloom, Jacqueline B Vo, Jo E Rodgers, Alana M Ferrari, Anju Nohria, Anita Deswal, Richard K Cheng, Michelle M Kittleson, Jenica N Upshaw, Nicolas Palaskas, Anne Blaes, Sherry-Ann Brown und 8 weitere

Journal of Cardiac Failure · 2025-02 · 31 (2) · 415-455

DOI: 10.1016/j.cardfail.2024.08.045 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cardiac Failure, 2025-02. Verfasst von Michelle Weisfelner Bloom und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, NYU Langone Health, NYU Grossman School of Medicine, New York, NY. Electronic address: michelle.bloom@nyulangone.org. Hauptthemen laut MEDLINE: Heart Failure, Neoplasms, Medical Oncology, Societies, Medical. Die Arbeit wurde bisher 126-mal zitiert (Crossref) und nennt 394 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCI NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure and cancer remain 2 of the leading causes of morbidity and mortality, and the 2 disease entities are linked in a complex manner. Patients with cancer are at increased risk of cardiovascular complications related to the cancer therapies. The presence of cardiomyopathy or heart failure in a patient with new cancer diagnosis portends a high risk for adverse oncology and cardiovascular outcomes. With the rapid growth of cancer therapies, many of which interfere with cardiovascular homeostasis, heart failure practitioners need to be familiar with prevention, risk stratification, diagnosis, and management strategies in cardio-oncology. This Heart Failure Society of America statement addresses the complexities of heart failure care among patients with active cancer diagnoses and cancer survivors. Risk stratification, monitoring and management of cardiotoxicity are presented across stages A through D heart failure, with focused discussion on heart failure with preserved ejection fraction and special populations, such as survivors of childhood and young-adulthood cancers. We provide an overview of the shared risk factors between cancer and heart failure, highlighting heart failure as a form of cardiotoxicity associated with many different cancer therapeutics. Finally, we discuss disparities in the care of patients with cancer and cardiac disease and present a framework for a multidisciplinary-team approach and critical collaboration among heart failure, oncology, palliative care, pharmacy, and nursing teams in the management of these complex patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureNeoplasmsMedical OncologySocieties, MedicalCardiologyAntineoplastic AgentsHumansCardiotoxicityUnited StatesCardio-Oncology

Stichwörter der Autor:innen

Heart failureand social determinantsbone marrow/stem cell transplantcancercancer survivorshipcancer treatment-related cardiac dysfunctioncardio-oncologycardiomyopathycardiotoxicityhealth disparitiesheart failure with preserved ejection fractionheart failure with reduced ejection fractionmechanical circulatory supportmultidisciplinary caremyocarditis

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Division of Cardiology, NYU Langone Health, NYU Grossman School of Medicine, New York, NY. Electronic address: michelle.bloom@nyulangone.org.
  • Radiation Epidemiology Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, Bethesda, MD.
  • Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC.
  • Division of Hematology/ Oncology, University of Virginia Health, Charlottesville, VA.
  • Cardio-Oncology Program, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.
  • Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston, TX.

Förderung

  • NHLBI NIH HHS
  • NCI NIH HHS
  • NIA NIH HHS
  • National Academy of Sciences

Zitieren

APA

Bloom, M. W., Vo, J. B., Rodgers, J. E., Ferrari, A. M., Nohria, A., Deswal, A., Cheng, R. K., Kittleson, M. M., Upshaw, J. N., Palaskas, N., Blaes, A., Brown, S. A., Ky, B., Lenihan, D., Maurer, M. S., Fadol, A., Skurka, K., Cambareri, C., Chauhan, C., & Barac, A. (2025). Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America. Journal of Cardiac Failure, 31(2), 415-455. https://doi.org/10.1016/j.cardfail.2024.08.045

Vancouver

Bloom MW, Vo JB, Rodgers JE, Ferrari AM, Nohria A, Deswal A, et al. Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America. Journal of Cardiac Failure. 2025;31(2):415-455. doi:10.1016/j.cardfail.2024.08.045

BibTeX
@article{Bloom2025,
  author = {Bloom, Michelle Weisfelner and Vo, Jacqueline B and Rodgers, Jo E and Ferrari, Alana M and Nohria, Anju and Deswal, Anita and Cheng, Richard K and Kittleson, Michelle M and Upshaw, Jenica N and Palaskas, Nicolas and Blaes, Anne and Brown, Sherry-Ann and Ky, Bonnie and Lenihan, Daniel and Maurer, Mathew S and Fadol, Anecita and Skurka, Kerry and Cambareri, Christine and Chauhan, Cynthia and Barac, Ana},
  title = {Cardio-Oncology and Heart Failure: a Scientific Statement From the Heart Failure Society of America},
  journal = {Journal of Cardiac Failure},
  year = {2025},
  volume = {31},
  number = {2},
  pages = {415--455},
  doi = {10.1016/j.cardfail.2024.08.045}
}
Kostenlos starten →